지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
이용수
초록· 키워드
오류제보하기
Background : Triflusal is a new platelet aggregation inhibitor structurally related to acetylsalicylic acid. We evaluated the inhibitory effects of triflusal on platelet aggregation and tried to determine adequate dosage of triflusal in ischemic stroke patients. Methods : Twenty patients were selected from those who had an ischemic stroke. The daily triflusal dosage was increased by 300 mg every 2 weeks starting from 300 mg/d to 900 mg/d. Platelet aggregation tests were done every 2 weeks during a 6-week period initiating at the beginning of the study. Results : Triflusal inhibited the platelet aggregation induced by epinephrine, collagen, and ADP. Epinephrineinduced platelet aggregation was inhibited most effectively. The percentage of the significant inhibitory responder(> 40% of inhibition) for platelet aggregation induced by epinephrine was increased as the daily dosage was raised: 38% with 300 mg/d, 88% with 600 mg/d, and 100% with 900 mg/d. The difference between 300 mg/d and 600 mg/d was statistically significant(p=.005) but that between 600 mg/d and 900 mg/d was not. The percentage of the significant inhibitory responder for platelet aggregation induced by collagen and ADP was also increased as the daily dosage multiplies. The adverse effects of triflusal(e.g, epigastric soreness and nausea) were observed in 4 of 20 patients(20%) as the dosage increases. Conclusion : Triflusal inhibited the platelet aggregation induced by epinephrine, collagen, and ADP in ischemic stroke patients. These data suggest that the optimal dosage of triflusal for patients with ischemic stroke is 900 mg/d but it can be reduced to 600 mg/d in consideration of the increase of the severe adverse effects at higher dosage. Korean Journal of Stroke 2000;2(2): 186~190
목차
등록된 정보가 없습니다.
참고문헌 (0)
참고문헌 신청함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Determination of triflusal in human plasma by high performance liquid chromatography with automated column switching system
대한약학회 학술대회
2002 .01
-
Triflusal과 Ibudilast 동시처리에 의한 혈소판응집 및 혈액응고 억제효과
약학회지
2012 .01
-
Effects of Triflusal and Clopidogrel on the Secondary Prevention of Stroke Based on Cytochrome P450 2C19 Genotyping
대한뇌졸중학회지
2017 .01
-
Effect of Triflusal on Primary Vascular Dysregulation Compared with Aspirin: A Double-Blind, Randomized, Crossover Trial
Yonsei Medical Journal
2015 .01
-
Acute Ischemic Stroke Associated with Essential Thrombocythemia and Suspected Platelet Aggregation in Intracranial Artery
대한뇌졸중학회지
2011 .01
-
Pharmacokinetic Study of Triflusal in Human Plasma by High Performance Liquid Chromatography with Automated Column Switching System
한국응용약물학회 추계학술발표논문집
2002 .01
-
죽상 동맥경화증과 연관된 허혈성 뇌졸중 환자에서 클로피도그렐의 혈소판 응집억제효과 및 내성에 대한 연구
대한뇌졸중학회지
1999 .01
-
트리플루살 캅셀의 생물학적 동등성 평가
The journal of applied pharmacology : the official journal of the Korean Society of Applied Pharmacology
2001 .01
-
허혈성 뇌졸중의 이차예방을 위한 항혈전제 치료
뇌신경재활
2014 .01
-
뇌졸중 환자에게 아스피린과 클로피도그렐 내성
대한뇌졸중학회지
2009 .01
-
뇌졸중 위험지표로서의 일반혈액검사 소견에 대한 환자 - 대조군 연구
대한한방내과학회지
2007 .01
-
Risk Factors and Biomarkers of Ischemic Stroke in Cancer Patients
대한뇌졸중학회지
2014 .01
-
Metabolite kinetics of triflusal to 2-hydroxy-4-trifluoromethyl benzoic acid in rats
대한약학회 학술대회
2000 .01
-
뇌졸중 환자의 시기에 따른 평균 혈소판 요소의 변화
Annals of Rehabilitation Medicine
2005 .01
-
대학병원에 입원한 허혈뇌졸중 환자들의 10년간 임상특성의 시계열 변동 분석(1999~2008년)
대한뇌졸중학회지
2010 .01
-
허혈뇌졸중의 중증도와 장애 정도에 대한 뇌졸중 위험인자와의 연관성
대한뇌졸중학회지
2012 .01
-
Trends in Incident and Recurrent Rates of First-Ever Ischemic Stroke in Taiwan between 2000 and 2011
대한뇌졸중학회지
2016 .01
-
허혈성 뇌졸중 환자의 뇌졸중 지식과 재발염려가 건강행위에 미치는 영향
성인간호학회지
2017 .06
이 논문의 저자 정보
최근 본 자료
댓글(0)
0